PIK3CD and cancer: However, due to earlier problems, such as unfavorable pharmacokinetic profiles and high in vivo toxicity, there is a continually growing need to discover novel PI3K and/or mTOR inhibitors for further development into therapeutic candidates for cancer treatment [11].